$Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial$

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

ABSTRACT Backgrounds Mitoxantrone hydrochloride liposome (Lipo‐MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo‐MIT, and dexamethasone...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ya‐Lan Zhou, Jin‐Qiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Li‐Ping Su, Wen‐Ming Chen, Guang‐Zhong Yang
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	Cancer Medicine
Subjects:	efficacy mitoxantrone hydrochloride liposome relapsed/refractory multiple myeloma safety
Online Access:	https://doi.org/10.1002/cam4.70890
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia
by: Ni Lu, et al.
Published: (2025-05-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

The clinical application of mitoxantrone hydrochloride tracing in endoscopic radical resection of thyroid carcinoma
by: Xiaozhou Cheng, et al.
Published: (2025-07-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Effects of the mitoxantrone thermosensitive liposome nanodelivery system on prostate cancer in vivo and in vitro
by: Yuan Gao, et al.
Published: (2025-05-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer
by: Dechuang Jiao, et al.
Published: (2025-02-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01)

CMOEP regimen in the treatment of untreated peripheral T-cell lymphoma: a multicenter, single-arm, phase I study
by: Jingwei Yu, et al.
Published: (2025-04-01)

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma
by: Wenjiao Tang, et al.
Published: (2024-07-01)

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)

Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients Mitoxantrone na esclerose múltipla secundária progressiva relato de 18 casos
by: María Belén Montú, et al.
Published: (2005-06-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

Acute myeloid leukaemia induced by mitoxantrone: case report Leucemia mielóide aguda induzida por mitoxantrone: relato de caso
by: Walter Oleschko Arruda, et al.
Published: (2005-06-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma
by: DU Fang, et al.
Published: (2025-01-01)

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
by: Francesca Gay, et al.
Published: (2025-03-01)

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
by: Carmen Tsang, et al.
Published: (2025-07-01)

Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma
by: AV Petrov, et al.
Published: (2017-07-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Successful treatment of gastric relapse in multiple myeloma with bortezomib after autologous hematopoietic stem cell transplantation (autoHSCT)
by: Serdar Sivgin
Published: (2013-01-01)

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review
by: Chen B, et al.
Published: (2025-04-01)

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
by: M. V. Solovev, et al.
Published: (2024-12-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer
by: Jingshu Wang, et al.
Published: (2025-01-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

Functional Liposomes Improve the Oral Absorption of Lurasidone Hydrochloride by Overcoming Multiple Absorption Barriers and Eliminating Food Effect
by: Song T, et al.
Published: (2025-04-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)